Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q2 2023 call → NOThe question asks whether management explains the company's business direction by narrating what its counterparties are themselves doing and scaling. I need to check if the transcript shows management describing specific customers' or partners' growth trajectories as the driver of the company's own coming volume. Looking through the transcript, management discusses: - New product launches (eVerest, eVoS, FluorOptic) - Design wins across markets - Factory expansions (Thailand, Mexicali) - Supply chain improvements - Market commentary by segment For semiconductor: "We generated record revenue in the high voltage part of our semiconductor business, largely due to continued strong demand from ion implant OEMs." This mentions OEMs but doesn't describe their specific trajectories. For industrial/medical: "We secured notable design wins and precision coating, industrial laser and 3D printing applications. In medical, we won major designs in Electrosurgery, Imaging, and Life Science applications." These are design wins, not descriptions of counterparties' own scaling. For data center: "Sales to several hyperscale customers grew sequentially fueled by demand for AI processing capability." This mentions hyperscale customers but doesn't describe their specific build-outs or trajectories. The management's forward account is mostly about: - Their own new products and design wins - Their own operational efficiency efforts - Market conditions (semiconductor correction, component availability) - Their own factory expansions They don't narrate specific counterparties' own ramps, launches, or build-outs as the driver of their coming volume. The design wins are mentioned but not described as early-stage trajectories of specific customers that will carry the company forward. The discussion is more about their own product launches and market positioning. The answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.